Lay Line Genomics S.p.A.

Glenmark Pharmaceuticals is moving ahead in the UK with the development of GBR-900, its "derisked" first in class monoclonal antibody for chronic pain targeting tyrosine kinase A (TrkA), the receptor

Glenmark's chairman and managing director, Glenn Saldanha, believes that key emerging markets now caught up in a vortex of regulatory change will deliver their promise in the long run, although the sh

In a significant move that may switch the image of India in biologics from a follower to a leader, Glenmark Pharmaceuticals has granted French drugs giant Sanofi a licence for the development and comm

Glenmark Pharmaceuticals is developing an anti-CD19 monoclonal antibody for the potential treatment of B-cell malignancies such as non-Hodgkin's lymphoma (NHL). This is Glenmark's first novel molecule